Testing a new drug combo for advanced melanoma after progression on immunotherapy
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (iparomlimab and tuvonralimab) plus bevacizumab for people with advanced melanoma whose cancer got worse after prior immunotherapy. The goal is to see if this new combination can help when standard treatments stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage 3 or 4 melanoma that cannot be removed by surgery.
- Your melanoma got worse within 12 weeks after at least two doses of an immunotherapy drug (like a PD-1 or PD-L1 inhibitor).
- If you have a BRAF, CKIT, or NRAS gene mutation, you must have already tried targeted therapy.
- You are in generally good health with a life expectancy of at least 3 months.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
This trial tests a new drug, LBL-024, either by itself or combined with another drug (LBL-007 or toripalimab) in people with advanced melanoma. The goal is to see if these combinations can shrink tumors or slow cancer growth.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. The drugs are designed to help your immune system fight the cancer while chemotherapy attacks it directly.
This trial tests a new combination of drugs (iparomlimab, tuvoraleimab, bevacizumab, and chemotherapy) as a first or second treatment for advanced acral or mucosal melanoma. It aims to see if this mix can help shrink or control the cancer.
Hear when a new CTLA-4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.